Amgen Inc.

27/08/2024 | News release | Distributed by Public on 27/08/2024 12:12

Amgen Expands No Cost Cholesterol Testing Program to Help Address Leading Public Health Crisis

High LDL-C or 'bad cholesterol' is a leading modifiable risk factor for heart attack and stroke. Yet many remain unaware of their high LDL levels due to the absence of symptoms.1

Over the past year, Amgen has helped thousands of people take important steps to learn more about their heart health through its no cost LDL-C testing program. As part of this effort, Amgen is making it even easier for communities across the nation to improve access to cholesterol testing. Individuals can now obtain an LDL-C test at no cost to them at approximately 1,000 MinuteClinic locations, found inside select CVS Pharmacy stores nationwide.

Amgen will also continue to offer no cost LDL-C home and lab tests for individuals who sign-up. More information about all LDL-C testing options is available at WhatismyLDL.com.*

Through the collective efforts of cardiovascular organizations and experts, we've helped thousands of people obtain no cost LDL-C tests, advanced cardiovascular care for millions of patients and accelerated programs that address inequities in heart health. This initiative is another example of how we are advancing our bold ambition to reduce the number of heart attacks and strokes by half by 2030.

- Murdo Gordon, executive vice president, Global Commercial Operations at Amgen

"Heart attack and stroke can be reduced through early detection and management of LDL-C levels," said Creagh Milford, D.O., MPH, president, Retail Health, CVS Health. "Cholesterol screenings are an important tool to help patients understand their cardiovascular health."

References

  1. Tsao C, Aday A, Almarzooq Z, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001052?utm_campaign=sciencenews21-22&utm_source=science-news&utm_medium=phd-link&utm_content=phd-01-26-22 Accessed 12 August 2022.